# QSAR MODELING OF CARCINOGENICITY BASED ON LOCAL ATTRIBUTES OF SMILES AND SPECIAL CODES OF CYCLES (GLOBAL SMILES ATTRIBUTES) 

A. Chana, A. A. Toropov, A. P. Toropova and E. Benfenati<br>Istituto di Ricerche Farmacologiche "Mario Negri", Via La Masa 19, 20156, Milano, Italy

## Introduction

Carcinogenicity is an important endpoint for REACH, and typically for this endpoint many animals are used. Some in silico models exist, which in most of the cases are aimed to classify chemicals as carcinogenic or not. REACH requires an evaluation of the risk in case of the use of carcinogenic compounds, considering the exposure levels. For this, QSAR models, predicting a potency level, and not classifiers, may play a role. We developed QSAR models based on SMILES. Simplified molecular input line entry system (SMILES) has been used as elucidation of the molecular structure for quantitative structure - activity relationships which are aimed to predict carcinogenicity of large dataset that contains wide variety of organic compounds. Using the Monte Carlo method we constructed optimal descriptors, which are a mathematical function of composition of the SMILES elements together with special codes of cycles present in molecules. The codes of cycles are reflected a presence of: cycles with sizes 5 and 6 , cycles with hetero-atoms and condensed cycles.

## Materials \& Methods

Optimal descriptors calculated with simplified molecular input line entry system (SMILES) have been used for quantitative structure - property/activity relationships (QSPR/QSAR) [1-3]. In case of the optimal descriptors calculated with molecular graph (hydrogen filled) statistical characteristics of the models becomes better if their calculating includes information on cycles. Similar approach based on the SMILES-based optimal descriptors has indicated that statistical characteristics of the QSAR for carcinogenicity are also preferable (Table 1). Technique of blocking of rare SMILES attributes has been used. The discrimination of the SMILES attributes into rare and not rare was carried out with a special threshold limS. LimS is the minimal number of a SMILES attribute in the training set. If less than limS SMILES contain the attribute $S A k^{*}$, than $C W\left(S A k^{*}\right)=0.0$, i.e., the $S A k^{*}$ has no influence to the model.

Two versions of the SMILES-based optimal descriptors have been studied:

1. without cycle codes
$\mathrm{DCW}(\operatorname{limS})=\quad \mathrm{CW}(\mathrm{dC})+\Sigma \mathrm{CW}(\mathrm{SAk})$
(1)
2. with cycle codes

DCW (limS) $=\mathrm{CW}(\mathrm{CC})+\mathrm{CW}(\mathrm{dC})+\Sigma \mathrm{CW}$ (SAk)
where SAk are the SMILES attributes constructed with three consequent SMILES elements (i.e., one symbol, or two symbols which can not be examined separately , e.g., ' $\mathrm{Cl}^{\prime}$, ' $\mathrm{Br}^{\prime}$ ' dC is difference of number of carbon atoms in sp2 state minus number of carbon atoms in sp3 state; CC is the cycle code for a given SMILES. CW (x) is the correlation weight for $x$ ( $x$ is a SMILES attribute).

## Results \& Discussions



Table 1
Statistical characteristics of the Models, for different limN and two versions of the descriptors.

| Mo |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Training set, $\mathrm{n}=170$ |  |  |  |  |  | Calibration set, $\mathrm{n}=170$ Test set, $\mathrm{n}=61$ |  |  |  |  |  |
| imNI | Nact | Probe | , |  |  | r2 |  | F | r2 |  |  |
| 0 | 593 | 1 | 0.8168 | 0.607 | 749 | 0.8133 | 0.622 | 732 | 0.5259 | . 81 | 65 |
| 0 | 593 | 2 | 0.8211 | 0.600 | 771 | 0.8149 | 0.617 | 740 | 0.5386 | 0.968 | 69 |
| 0 | 593 | 3 | 0.8162 | 0.608 | 746 | 0.8156 | 0.625 | 743 | 0.4969 | 1.026 | 5 |
| 0 |  |  | 0.8180 | 0.605 | 755 | 0.8146 | 0.622 | 738 | 0.5205 | 0.988 | 64 |
| 1 | 469 | 1 | 0.8197 | 0.602 | 764 | 0.8176 | 0.630 | 753 | 0.5577 |  | 74 |
| 1 | 469 | 2 | 0.8173 | 0.606 | 751 | 0.8132 | 0.635 | 732 | 0.5960 | 0.901 | 87 |
| 1 | 469 | 3 | 0.8193 | 0.603 | 762 | 0.8147 | 0.64 | 738 | 0.608 | 0.891 | 92 |
| 1 |  |  | 0.8188 | 0.603 | 759 | 0.8152 | 0.63 | 74 | 0.58 | 0.927 | 84 |
| 2 | 311 | 1 | 0.7643 | 0.688 | 545 | 0.7557 | 0.69 | 520 | 0.6847 | 0.760 | 128 |
| 2 | 311 | 2 | 0.7648 | 0.687 | 546 | 0.7651 | 0.686 | 547 | 0.693 | 0.784 | 133 |
| 2 | 311 | 3 | 0.7678 | 0.683 | 556 | 0.7614 | 0.691 | 536 | 0.6938 | 0.773 | 134 |
| 2 |  |  | 0.7656 | 0.686 | 549 | 0.7608 | 0.692 | 53 | 0.6906 |  |  |
| 3 | 240 | 1 | 0.7120 | 0.761 | 415 | 0.7111 | 0.76 | 41 | 0.657 | 0.790 | 113 |
| 3 | 240 | 2 | 0.7105 | 0.763 | 412 | 0.7093 | 0.766 | 410 | 0.6917 |  | 132 |
| 3 | 240 | 3 | 0.7093 | 0.764 | 410 | 0.7090 | 0.770 | 409 | 0.6674 | 0.758 | 118 |
| 3 |  |  | 0.7106 | 0.763 | 413 | 0.7098 | 0.767 | 411 | 0.6723 | 0. | 121 |
| 4 | 205 | 1 | 0.6628 | 0.823 | 330 | 0.6678 | 0.815 | 338 | 0.7377 | 0.641 | 166 |
| 4 | 205 | 2 | 0.6669 | 0.818 | 336 | 0.6691 | 0.813 | 340 | 0.7083 | 0.6 | 143 |
| 4 | 205 | 3 | 0.6677 | 0.817 | 338 | 0.6681 | 0.817 | 338 | 0.7227 | - | 154 |
| 4 |  |  | 0.6658 | 0.819 | 335 | 0.6683 | 0.815 | 339 | 0.7229 | 0.65 | 154 |
| 5 | 176 |  | 0.6358 | 0.855 | 293 | 0.6407 | 0.851 | 300 | 0.6775 | 0.72 | 124 |
| 5 | 176 | 2 | 0.6337 | 0.858 | 291 | 0.6349 | 0.857 | 292 | 0.6812 | 0.72 | 126 |
| 5 | 176 | 3 | 0.6253 | 0.868 | 280 | 0.6296 | 0.863 | 286 | 0.6795 | 0.71 | 125 |
| 5 |  |  | 0.6316 | 0.860 | 288 | 0.6351 | 0.857 | 292 | 0.6 |  |  |


|  |  | Training set, $n=170$ |  |  |  | Calibration set, $\mathrm{n}=170$ |  |  | Test set, $\mathrm{n}=61$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| imNI | Nact | Probe | r2 | s | F | r2 | s | F | r2 | S | F |
| 0 | 593 | 1 | 0.8198 | 0.602 | 764 | 0.8195 | 0.603 | 763 | 0.6050 | 0.848 | 90 |
| 0 | 593 | 2 | 0.8251 | 0.593 | 793 | 0.8209 | 0.606 | 770 | 0.6069 | 0.860 | 91 |
| 0 | 593 | 3 | 0.8245 | 0.594 | 789 | 0.8216 | 0.610 | 774 | 0.6212 | 0.809 | 97 |
| 0 |  |  | 0.8231 | 0.596 | 782 | 0.8207 | 0.606 | 769 | 0.6110 | 0.839 | 93 |
| 1 | 469 | 1 | 0.8240 | 0.595 | 787 | 0.8196 | 0.637 | 763 | 0.6504 | 0.818 | 110 |
| 1 | 469 | 2 | 0.8230 | 0.596 | 781 | 0.8208 | 0.636 | 770 | 0.6531 | 0.825 | 111 |
| 1 | 469 | 3 | 0.8226 | 0.597 | 779 | 0.8210 | 0.625 | 771 | 0.6152 | 0.884 | 94 |
| 1 |  |  | 0.8232 | 0.596 | 782 | 0.8205 | 0.633 | 768 | 0.6395 | 0.842 | 105 |
| 2 | 311 | 1 | 0.7699 | 0.680 | 562 | 0.7591 | 0.696 | 529 | 0.7615 | 0.656 | 188 |
| 2 | 311 | 2 | 0.7682 | 0.682 | 557 | 0.7646 | 0.686 | 546 | 0.7492 | 0.671 | 176 |
| 2 | 311 | 3 | 0.7647 | 0.688 | 546 | 0.7630 | 0.692 | 541 | 0.7577 | 0.66 | 185 |
| 2 |  |  | 0.7676 | 0.683 | 555 | 0.7622 | 0.692 | 539 | 0.7561 | 0.665 | 183 |
| 3 | 240 | 1 | 0.7123 | 0.760 | 416 | 0.7140 | 0.758 | 419 | 0.7145 | 0.699 | 148 |
| 3 | 240 | 2 | 0.7199 | 0.750 | 432 | 0.7199 | 0.754 | 432 | 0.7259 | 0.683 | 156 |
| 3 | 240 | 3 | 0.7129 | 0.760 | 417 | 0.7132 | 0.759 | 418 | 0.7179 | 0.677 | 150 |
| 3 |  |  | 0.7150 | 0.757 | 422 | 0.7157 | 0.757 | 423 | 0.7194 | 0.686 | 151 |
| 4 | 205 | 1 | 0.6734 | 0.810 | 346 | 0.6784 | 0.806 | 354 | 0.7370 | 0.635 | 165 |
| 4 | 205 | 2 | 0.6731 | 0.810 | 346 | 0.6762 | 0.807 | 351 | 0.7174 | 0.658 | 150 |
| 4 | 205 | 3 | 0.6621 | 0.824 | 329 | 0.6834 | 0.802 | 363 | 0.7301 | 0.644 | 160 |
| 4 |  |  | 0.6695 | 0.815 | 341 | 0.6793 | 0.805 | 356 | 0.7282 | 0.646 | 158 |
| 5 | 176 | 1 | 0.6466 | 0.843 | 307 | 0.6516 | 0.838 | 314 | 0.6019 | 0.806 | 89 |
| 5 | 176 | 2 | 0.6402 | 0.850 | 299 | 0.6601 | 0.831 | 326 | 0.6328 | 0.765 | 102 |
| 5 | 176 | 3 | 0.6379 | 0.853 | 296 | 0.6471 | 0.844 | 308 | 0.6491 | 0.744 | 109 |
| 5 |  |  | 0.6415 | 0.849 | 301 | 0.6529 | 0.838 | 316 | 0.6279 | 0.772 | 100 |

Cycle codes have been defined as the following
\&(5-member cycles number)(6-member cycles number)(heteroatoms number)
Figure 2
Example of a compound of view


## Conclusions

One can see from Table 1 and Figure 1 that:
i) better results for both schemes take place if the $\lim S=2$;
ii) the model that involves cycles codes gives better prediction for the carcinogenicity of external test set.

## References

[1] A. A. Toropov, E. Benfenati, Eur. J. Med. Chem. 42 (2007) 606-613
[2] A. Toropov, E. Benfenati, Cur. Drug Disc. Tech., 4 (2007) 77-116
[3] A. A. Toropov, E. Benfenati, Bioorg. Med. Chem. 16 (2008) 4801-4809
[4] Th. Hanser, Ph. Jauffret, G. Kaufmann J. Chem. Inf. Comput. Sci. 36(1996) 1146-1152

